{"id":585,"date":"2022-02-15T23:08:05","date_gmt":"2022-02-15T23:08:05","guid":{"rendered":"https:\/\/medicalmarijuanainc.com\/?p=1013445"},"modified":"2022-02-15T23:08:05","modified_gmt":"2022-02-15T23:08:05","slug":"medical-marijuana-inc-subsidiary-kannaway-celebrates-best-revenue-month-in-company-history-for-south-africa-and-japan-divisions-in-january-2022","status":"publish","type":"post","link":"https:\/\/medicalmarijuanainc.com\/2022\/02\/15\/medical-marijuana-inc-subsidiary-kannaway-celebrates-best-revenue-month-in-company-history-for-south-africa-and-japan-divisions-in-january-2022\/","title":{"rendered":"Medical Marijuana, Inc. Subsidiary Kannaway\u00ae Celebrates Best Revenue Month in Company History for South Africa and Japan Divisions in January 2022"},"content":{"rendered":"
SAN DIEGO, CA, Feb. 15, 2022 (GLOBE NEWSWIRE) — via\u00a0NewMediaWire —<\/u><\/a>\u00a0<\/a>Medical Marijuana, Inc.<\/u><\/a>\u00a0(OTC: MJNA) (the \u201cCompany\u201d), the first-ever publicly traded cannabis company in the United States that launched the world\u2019s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today that its subsidiary\u00a0Kannaway\u00ae<\/u><\/a>\u00a0achieved its largest revenue month in the company\u2019s history in its Japan and South Africa divisions in January 2022.<\/p>\n According to Business Insider Africa, Africa\u2019s cannabis industry is projected to grow beyond a\u00a0$7 billion valuation by 2023<\/u><\/a>. Reach and Markets highlights that the Asia-Pacific market is also expected to grow exponentially with a\u00a0CAGR of 28.6% from 2020 to 2027<\/u><\/a>.<\/p>\n \u201cBeing able to achieve four best revenue months in a row in the Japan market has been both a great way to end 2021 and an inspiring way to start 2022,\u201d said Medical Marijuana, Inc. CEO Blake Schroeder. \u201cNow that we\u2019ve reached this milestone in South Africa as well, we anticipate that both regions will be major market areas for us this year and beyond.\u201d<\/p>\n To learn more about Kannaway\u00ae, please visit the Company online at\u00a0https:\/\/www.kannaway.com\/<\/u><\/a>.<\/p>\n About Kannaway\u00ae About Medical Marijuana, Inc. Medical Marijuana, Inc.’s headquarters is in\u00a0San Diego, California, and additional information is available at\u00a0OTCMarkets.com<\/u><\/a>\u00a0or by visiting\u00a0www.medicalmarijuanainc.com<\/u><\/a>. To see Medical Marijuana, Inc.’s corporate video,\u00a0click here<\/u><\/a>.<\/p>\n FORWARD-LOOKING DISCLAIMER FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE LEGAL DISCLOSURE CONTACT:<\/b><\/p>\n Public Relations Contact: Investor Relations Contact: SAN DIEGO, CA, Feb. 15, 2022 (GLOBE NEWSWIRE) — via\u00a0NewMediaWire —\u00a0Medical Marijuana, Inc.\u00a0(OTC: MJNA) (the \u201cCompany\u201d), the first-ever publicly traded cannabis company in the United States that launched the world\u2019s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today that its subsidiary\u00a0Kannaway\u00ae\u00a0achieved its largest revenue month in the company\u2019s history in its Japan and […]<\/p>\n","protected":false},"author":1,"featured_media":586,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[2],"tags":[],"class_list":["post-585","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-releases"],"yoast_head":"\n
\n<\/b>Kannaway\u00ae<\/u><\/a>\u00a0is a network sales and marketing company specializing in the sales and marketing of hemp-based botanical products. Kannaway\u00ae currently hosts weekly online sales meetings and conferences across the United States, offering unique insight and opportunity to sales professionals who are desirous of becoming successful leaders in the sale and marketing of hemp-based botanical products.<\/p>\n
\n<\/b>We are a company of firsts\u00ae<\/u><\/a>. Medical Marijuana, Inc. (MJNA<\/u><\/a>) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by\u00a0Kannaway\u00ae<\/u><\/a>\u00a0and\u00a0HempMeds\u00ae<\/u><\/a>; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including\u00a0AXIM\u00ae Biotechnologies, Inc<\/u><\/a>.<\/u><\/a>\u00a0and\u00a0Neuropathix<\/u><\/a>. Medical Marijuana, Inc. was named a top CBD producer by\u00a0CNBC<\/u><\/a>. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of\u00a0Brazil,\u00a0Mexico,\u00a0Argentina, and\u00a0Paraguay\u00a0and is a leader in the development of international markets. The company’s flagship product\u00a0Real Scientific Hemp Oil<\/u><\/a>\u00a0has been used in several successful clinical studies throughout\u00a0Mexico\u00a0and\u00a0Brazil\u00a0to understand its safety and efficacy.<\/p>\n
\n<\/b>This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and\/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.<\/p>\n
\n<\/b>These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.<\/p>\n
\n<\/b>Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.<\/p>\n
\nKathryn Brown
\nAccount Director
\nCMW Media
\nP. 858-264-6600
\nkathryn@cmwmedia.com
\nwww.cmwmedia.com<\/p>\n
\nP. (858) 283-4016
\nInvestors@medicalmarijuanainc.com<\/p>\n","protected":false},"excerpt":{"rendered":"